{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:01:10Z","timestamp":1794852070966,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Mildred Scheel Early Career Center Wuerzburg"],"award-info":[{"award-number":["Mildred Scheel Early Career Center Wuerzburg"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["2505-0-0"],"award-info":[{"award-number":["2505-0-0"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hiege-Stiftung gegen Hautkrebs"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHI 510\/12\u20131"],"award-info":[{"award-number":["SCHI 510\/12\u20131"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Germany's Excellence Strategy\u2014EXC2180\u2013390900677"],"award-info":[{"award-number":["Germany's Excellence Strategy\u2014EXC2180\u2013390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"publisher","award":["Open Access Publication Fund"],"award-info":[{"award-number":["Open Access Publication Fund"]}],"id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum M\u00fcnster","id":[{"id":"https:\/\/ror.org\/01856cw59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAF\n                      <jats:sup>V600<\/jats:sup>\n                      mutations (BRAF\n                      <jats:sup>Mut<\/jats:sup>\n                      ). However, there is still a significant need for effective targeted therapies for patients with other melanoma subgroups characterized by constitutive MAPK activation, such as tumors with NRAS or NF-1 alterations (NRAS\n                      <jats:sup>Mut<\/jats:sup>\n                      , NF-1\n                      <jats:sup>LOF<\/jats:sup>\n                      ), as well as for patients with MAPK pathway inhibitor-resistant BRAF\n                      <jats:sup>Mut<\/jats:sup>\n                      melanomas, which commonly exhibit a reactivation of this pathway. p90 ribosomal S6 kinases (RSKs) represent central effectors of MAPK signaling, regulating cell cycle progression and survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      RSK activity and the functional effects of its inhibition by specific small molecule inhibitors were investigated in established melanoma cell lines and patient-derived short-term cultures from different MAPK pathway-hyperactivated genomic subgroups (NRAS\n                      <jats:sup>Mut<\/jats:sup>\n                      , BRAF\n                      <jats:sup>Mut<\/jats:sup>\n                      , NF-1\n                      <jats:sup>LOF<\/jats:sup>\n                      ). Real-time qPCR, immunoblots and flow cytometric cell surface staining were used to explore the molecular changes following RSK inhibition. The effect on melanoma cell growth was evaluated by various two- and three-dimensional in vitro assays as well as with melanoma xenograft mouse models. Co-cultures with gp100- or Melan-A-specific cytotoxic T cells were used to assess immunogenicity of melanoma cells and associated T-cell responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In line with elevated activity of the MAPK\/RSK signaling axis, growth and survival of not only BRAF\n                      <jats:sup>Mut<\/jats:sup>\n                      but also NRAS\n                      <jats:sup>Mut<\/jats:sup>\n                      and NF-1\n                      <jats:sup>LOF<\/jats:sup>\n                      melanoma cells were significantly impaired by RSK inhibitors. Intriguingly, RSK inhibition was particularly effective in three-dimensional growth settings with long-term chronic drug exposure and suppressed tumor cell growth of in vivo melanoma models. Additionally, our study revealed that RSK inhibition simultaneously promoted differentiation and immunogenicity of the tumor cells leading to enhanced T-cell activation and melanoma cell killing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, RSK inhibitors exhibited both multi-layered anti-tumor efficacy and broad applicability across different genomic melanoma subgroups. RSK inhibition may therefore represent a promising novel therapeutic strategy for malignant melanoma with hyperactivated MAPK signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02755-5","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T22:01:56Z","timestamp":1689717716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion"],"prefix":"10.1186","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-838X","authenticated-orcid":false,"given":"Corinna","family":"Kosnopfel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Wendlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Siewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Siedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Jayanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Schittek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"2755_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fcell.2016.00033","volume":"4","author":"C Wellbrock","year":"2016","unstructured":"Wellbrock C, Arozarena I. The Complexity of the ERK\/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol. 2016;4:33.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2755_CR2","first-page":"3728","volume":"8","author":"C Cohen","year":"2002","unstructured":"Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 2002;8(12):3728\u201333.","journal-title":"Clin Cancer Res"},{"issue":"6892","key":"2755_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"7","key":"2755_CR4","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"7653","key":"2755_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380.","journal-title":"Nature"},{"issue":"10","key":"2755_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239\u201346.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2755_CR7","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"2755_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med"},{"key":"2755_CR9","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1038\/ncomms6694","volume":"5","author":"GV Long","year":"2014","unstructured":"Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694.","journal-title":"Nat Commun"},{"issue":"22","key":"2755_CR10","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2755_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80\u201393.","journal-title":"Cancer Discov"},{"issue":"5","key":"2755_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jid.2017.01.013","volume":"137","author":"S Trousil","year":"2017","unstructured":"Trousil S, Chen S, Mu C, Shaw FM, Yao Z, Ran Y, et al. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. J Invest Dermatol. 2017;137(5):1135\u201343.","journal-title":"J Invest Dermatol"},{"issue":"49","key":"2755_CR13","doi-asserted-by":"publisher","first-page":"84616","DOI":"10.18632\/oncotarget.21388","volume":"8","author":"P Koelblinger","year":"2017","unstructured":"Koelblinger P, Dummer R. Targeted treatment of advanced NRAS-mutated melanoma. Oncotarget. 2017;8(49):84616\u20137.","journal-title":"Oncotarget"},{"issue":"16","key":"2755_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"26","key":"2755_CR15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"2755_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1042\/BJ20110289","volume":"441","author":"Y Romeo","year":"2012","unstructured":"Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441(2):553\u201369.","journal-title":"Biochem J"},{"key":"2755_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2017.04.016","volume":"48","author":"T Houles","year":"2018","unstructured":"Houles T, Roux PP. Defining the role of the RSK isoforms in cancer. Semin Cancer Biol. 2018;48:53\u201361.","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"2755_CR18","doi-asserted-by":"publisher","first-page":"35761","DOI":"10.18632\/oncotarget.16204","volume":"8","author":"C Kosnopfel","year":"2017","unstructured":"Kosnopfel C, Sinnberg T, Sauer B, Niessner H, Schmitt A, Makino E, et al. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. Oncotarget. 2017;8(22):35761\u201375.","journal-title":"Oncotarget"},{"issue":"1","key":"2755_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0002-9440(10)64719-0","volume":"156","author":"F Meier","year":"2000","unstructured":"Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, et al. Human melanoma progression in skin reconstructs\u202f: biological significance of bFGF. Am J Pathol. 2000;156(1):193\u2013200.","journal-title":"Am J Pathol"},{"issue":"10","key":"2755_CR20","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/ijc.22512","volume":"120","author":"B Schittek","year":"2007","unstructured":"Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 2007;120(10):2110\u20138.","journal-title":"Int J Cancer"},{"issue":"8","key":"2755_CR21","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/cancers12082328","volume":"12","author":"C Kosnopfel","year":"2020","unstructured":"Kosnopfel C, Sinnberg T, Sauer B, Niessner H, Muenchow A, Fehrenbacher B, et al. Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion. Cancers (Basel). 2020;12(8):2328.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2755_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1038\/jid.2013.82","volume":"133","author":"S Angermeyer","year":"2013","unstructured":"Angermeyer S, Hesbacher S, Becker JC, Schrama D, Houben R. Merkel cell polyomavirus-positive Merkel cell carcinoma cells do not require expression of the viral small T antigen. J Invest Dermatol. 2013;133(8):2059\u201364.","journal-title":"J Invest Dermatol"},{"key":"2755_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ebiom.2016.04.037","volume":"8","author":"T Sinnberg","year":"2016","unstructured":"Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, et al. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine. 2016;8:132\u201349.","journal-title":"EBioMedicine"},{"key":"2755_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1476-4598-13-194","volume":"13","author":"DJ Wong","year":"2014","unstructured":"Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, et al. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014;13:194.","journal-title":"Mol Cancer"},{"issue":"3","key":"2755_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.molonc.2014.01.003","volume":"8","author":"MS Carlino","year":"2014","unstructured":"Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 2014;8(3):544\u201354.","journal-title":"Mol Oncol"},{"issue":"15_suppl","key":"2755_CR26","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1200\/JCO.2020.38.15_suppl.3640","volume":"38","author":"F Janku","year":"2020","unstructured":"Janku F, Elez E, Iyer G, Yamamoto N, Tan DS-W, Stathis A, et al. Phase I dose-finding study of oral ERK1\/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations. J Clin Oncol. 2020;38(15_suppl):3640.","journal-title":"J Clin Oncol"},{"issue":"38","key":"2755_CR27","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1038\/onc.2012.472","volume":"32","author":"H Ray-David","year":"2013","unstructured":"Ray-David H, Romeo Y, Lavoie G, Deleris P, Tcherkezian J, Galan JA, et al. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance. Oncogene. 2013;32(38):4480\u20139.","journal-title":"Oncogene"},{"issue":"10","key":"2755_CR28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.jid.2016.12.033","volume":"137","author":"N Theodosakis","year":"2017","unstructured":"Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, et al. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. J Invest Dermatol. 2017;137(10):2187\u201396.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2755_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/pbc.24675","volume":"61","author":"MR Pambid","year":"2014","unstructured":"Pambid MR, Berns R, Adomat HH, Hu K, Triscott J, Maurer N, et al. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. Pediatr Blood Cancer. 2014;61(1):107\u201315.","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2755_CR30","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.1021\/acs.jmedchem.5b00450","volume":"58","author":"R Jain","year":"2015","unstructured":"Jain R, Mathur M, Lan J, Costales A, Atallah G, Ramurthy S, et al. Discovery of Potent and Selective RSK Inhibitors as Biological Probes. J Med Chem. 2015;58(17):6766\u201383.","journal-title":"J Med Chem"},{"key":"2755_CR31","doi-asserted-by":"crossref","unstructured":"Dunn SE, Jayanthan A, Huynh M-m, Flahive E, Pambid MR, Dorr A, et al. PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC) [abstract]. Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10\u201314; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl): Abstract nr P3\u201310\u201310; 2019. p. 2019 Dec 10\u201314","DOI":"10.1158\/1538-7445.SABCS19-P3-10-10"},{"key":"2755_CR32","doi-asserted-by":"crossref","unstructured":"Jayanthan A, Huynh M-m, Lee J, Los G, Yue L, Pambid MR, et al. PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models [abstract]. Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10\u201315 and May 17\u201321; Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1038; 2021. p. 2021 Apr 10\u201315 and May 17\u201321.","DOI":"10.1158\/1538-7445.AM2021-1038"},{"issue":"15_suppl","key":"2755_CR33","doi-asserted-by":"publisher","first-page":"e13043","DOI":"10.1200\/JCO.2021.39.15_suppl.e13043","volume":"39","author":"M Beeram","year":"2021","unstructured":"Beeram M, Chalasani P, Wang JS, Mina LA, Shatsky RA, Trivedi MS, et al. First-in-human phase 1\/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2021;39(15_suppl):e13043\u2013e.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2755_CR34","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/cas.15280","volume":"113","author":"M Ushijima","year":"2022","unstructured":"Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M. An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Cancer Sci. 2022;113(5):1731\u20138.","journal-title":"Cancer Sci"},{"issue":"19","key":"2755_CR35","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.cub.2005.08.050","volume":"15","author":"R Anjum","year":"2005","unstructured":"Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol. 2005;15(19):1762\u20137.","journal-title":"Curr Biol"},{"issue":"5443","key":"2755_CR36","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","volume":"286","author":"A Bonni","year":"1999","unstructured":"Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286(5443):1358\u201362.","journal-title":"Science"},{"issue":"1","key":"2755_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molcel.2008.12.020","volume":"33","author":"E Dehan","year":"2009","unstructured":"Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, et al. betaTrCP- and Rsk1\/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell. 2009;33(1):109\u201316.","journal-title":"Mol Cell"},{"issue":"10","key":"2755_CR38","first-page":"6260","volume":"13","author":"VM Rivera","year":"1993","unstructured":"Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J, et al. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol. 1993;13(10):6260\u201373.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2755_CR39","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/bcr2202","volume":"10","author":"AL Stratford","year":"2008","unstructured":"Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008;10(6):R99.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"2755_CR40","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","volume":"91","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994;91(14):6458\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2755_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.180.1.347","volume":"180","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347\u201352.","journal-title":"J Exp Med"},{"issue":"3","key":"2755_CR42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.immuni.2020.07.007","volume":"53","author":"M Effern","year":"2020","unstructured":"Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, et al. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity. 2020;53(3):564\u201380e9.","journal-title":"Immunity"},{"issue":"7420","key":"2755_CR43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136.","journal-title":"Nature"},{"issue":"25","key":"2755_CR44","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99(25):16168\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2755_CR45","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"2755_CR46","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225\u201331.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2755_CR47","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22890","volume":"2","author":"B Sapkota","year":"2013","unstructured":"Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology. 2013;2(1): e22890.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2755_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","volume":"3","author":"SD Bradley","year":"2015","unstructured":"Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3(6):602\u20139.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02755-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T23:30:57Z","timestamp":1689723057000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02755-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02755-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of human tissue for the generation of patient-derived melanoma short-term cultures and the isolation of melanocytes was approved by the respective local medical ethical committees (T\u00fcbingen: 43\/2008B01, 16\/2009B02, 40\/2009B02; W\u00fcrzburg: 241\/2014) and experiments were performed according to the Declaration of Helsinki Principles.All animal experiments were approved by the responsible regional authority (Regierungspr\u00e4sidium T\u00fcbingen, AZ HT1\/18) and conducted in accordance with the institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.E.D. and A.J. hold equity ownership of the RSK inhibitor PMD-026 (Phoenix Molecular Designs). All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}